Treatment Action Group releases a patent landscape investigating potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines.

On 4 November 2021, Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC) will co-host a webinar, 'Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies', to present the main findings of the upcoming report 'Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.'

This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

Take a short survey and help evaluate the first 10 years of the Global TB CAB!

Take a quick Community Advisory Board (CAB) compensation survey and help define how to best support CAB members!

The tools are meant to help build awareness of TB in communities, share information on the latest scientific and policy developments, and inform activism to address barriers to TB diagnosis, treatment, and care.

A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.